What We’re Reading

Each issue of the Topics, Trends & Updates email includes a summary of a recently published journal article, written by Christopher Hoffmann, MD, MPH, Principal Investigator of the HIV Clinical Guidelines Program. Dr. Hoffmann is an assistant professor of medicine at the Johns Hopkins University School of Medicine, Division of Infectious Diseases. 

Articles are chosen to highlight topics that are directly relevant to clinical practice in the U.S. and that are not already widely summarized by other authors. 

All titles are listed below. If you would like to receive the Topics, Trends & Updates email, please subscribe

2018

2017

2016

 

Is Long-Term Antiretroviral Use Associated With Weight Gain? (3/18)

Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine

As people with HIV age, accelerated weight gain and increased risks of heart disease and metabolic disease may follow. Unhealthy weight gain can be distressing to patients and increases the risk of complications of obesity. Some patients wonder whether their weight gain is related to the antiretroviral (ARV) agents they take to control HIV disease. Although some older and now rarely used ARVs, such as stavudine and indinavir, are known to cause accumulation of visceral adipose tissue and lipodystrophy, there is not much evidence to suggest that ARVs commonly in use now are responsible for unhealthy weight gain.

A recent study by Norwood and colleagues (Norwood J, Turner M, Bofill C, et al. J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):527-531) used retrospective observational data extracted from a single electronic medical record system to assess changes in weight by ARV class and agent. Included in the analysis were data for 495 adults (see details in table below) who were treated for at least 2 years with an efavirenz (EFV)-based regimen and then: 1) switched to an integrase strand transfer inhibitor (INSTI)-based regimen; 2) switched to a protease inhibitor (PI)-based regimen; or 3) continued with the EFV-based regimen for at least 18 months and maintained an HIV RNA level <1,000 c/mL during that 18-month period. Patients who became pregnant during the 2-year EFV period or the 18-month follow-up period were excluded. The first patient switch to a PI-based regimen occurred in 2005. The first patient switch to an INSTI-based-regimen occurred in 2010. Data accumulated through December 2015 were included in the analysis. To compare patient data over time, the researchers applied linear mixed models adjusted for age, sex, race, baseline weight, baseline CD4 cell count, and total time on ARVs.

Table: Study Groups and Mean Weight Gain 18 Months Post ARV Switch
  Number (% of Total Study N) CD4 Count at Switch Mean Weight Gain
Switched to INSTI 136 (27%); 14% women 662 cells/mm3 2.9 kg
Switched to PI 34 (7%); 29% women 156 cells/mm3 0.7 kg
Stayed on EFV 325 (66%); 14% women 576 cells/mm3 0.9 kg

Among the patients who switched to INSTIs, those on dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC) gained a mean of 5.3 kg compared with 2.8 kg gained among those who switched to either raltegravir (RAL) or elvitegravir (EVG); data for the two INSTIs were combined in the comparison. The increase in weight among patients on INSTI-containing regimens was statistically greater than the increases among patients who continued with EFV or switched to PI-containing regimens. Given the association of diabetes with obesity, the researchers attempted to assess for HbA1c differences across the study groups, but data were insufficient for meaningful comparisons.

The limitations of this study are that it is retrospective, has a small sample size, and grouped multiple regimens in analysis. In addition, the changes in regimens reflect trends in antiretroviral therapy, with switches to PIs starting in 2005 and switches to INSTIs starting later, in 2010. Nonetheless, the results are intriguing and point to a need for further study to better understand INSTI- and other ARV-associated weight gain. If an association is confirmed, then it will be important to identify and mitigate potential consequences, such as increased risk for metabolic and cardiovascular disease.

Understanding the long-term effects of ARV use is crucial to maintaining the health of people aging with HIV and to protecting the health of those starting ART now. Studies such as this one by Norwood and colleagues may not prompt an immediate change in prescribing practice, but it should prompt our attention to weight gain among patients taking INSTIs.

Finding Those Lost by the U.S. HIV Care Continuum (4/18)

Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine

Retention in HIV care is a longstanding problem. A 2010 meta-analysis of U.S. studies reported retention of approximately 60% and identified retention as a particularly weak point along the HIV care cascade [Marks G, Gardner L, Craw J, Crepaz N. AIDS 2010 Nov 13;24(a7)]. The CDC’s 2017 analysis of the U.S. HIV care continuum estimated that, in 2014, there were 1.1 million people in the United States with HIV, of whom 85% were diagnosed, 62% were in care, and 49% were virally suppressed. 

In their 2016 mathematical modeling study of the U.S. epidemic, Shah and colleagues identified improved retention in HIV care as the most efficient and cost-effective approach to reducing new HIV infections and HIV-associated mortality [Lancet HIV 2016 Mar 3(3)]. However, subpopulations are lost in the broad approach taken by modeling studies, which means that groups at both ends of the spectrum (high and low levels of retention in care) are generally not identified. Because effective retention strategies differ by population, identifying groups likely to be lost from the care continuum may help guide development of effective retention interventions. 

One group at particular risk of being lost from care is postpartum women. A study that included 695 mothers in Philadelphia who received prenatal HIV care from 2005 to 2011 determined that only 38% were retained in HIV care 90 days postpartum, and only 31% were virally suppressed 12 months after giving birth [Adams JW, Brady KA, Michael YL, et al. Clin Infect Dis 2015 Dec;61(12)].

A recently published article reports on postpartum retention in care among 22 women with perinatally-acquired HIV who delivered at Grady Memorial Hospital in Atlanta, GA, between 2011 and 2016 [Meade CM, Hussen SA, Momnplaisir F, et al. AIDS Care 2018 Apr; 30(4)]. The mean age of the women was 21 years, and 14 were in their first pregnancy. Thirteen (59%) were in HIV care before becoming pregnant, and all received antiretroviral therapy during the prenatal period. At the time of delivery, 59% (13) had a viral load <200 copies/mL. Perinatal transmission occurred in one case. Within 12 months postpartum, only 4 (20%) of the women were retained in HIV care and 3 (15%) were virally suppressed. At 24 months postpartum, just two (12%) were retained in care, and none were virally suppressed.

Although Meade’s study involved a small number of women, its description of a subpopulation with especially low rates of retention in care is valuable. Postpartum women with perinatally-acquired HIV achieved just half the retention and viral load suppression reported for postpartum women with HIV overall, and the rate of retention among both groups is low. Clearly, much work is needed to find effective strategies to keep postpartum women engaged in care and virally suppressed.

This example demonstrates the value of identifying specific populations at risk of being lost from care and assessing care needs on the micro level to target and fine tune patient-centered support strategies. As improvements are made at all points along the HIV care continuum, the needs of those for whom standard approaches to retention are not effective must be addressed. More research is needed to identify those at highest risk for attrition and develop context-specific approaches to keeping them engaged in HIV care.

Chronic Comorbidities among People Living with HIV Infection (1/18)

Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine

As a result of potent and tolerable antiretroviral therapy (ART), people with HIV infection (PLWH) are living longer. However, rates of chronic, non-communicable end-organ diseases are higher in PLWH than in people of similar ages who do not have HIV infection. Even when adjusted for traditional risk factors, rates of myocardial infarction and other comorbidities, including liver disease, kidney disease, and several cancers, are increased among PLWH [Drozd DR, Kitahata MM, Althoff KN, et al. J Acquir Immune Defic Syndr. 2017 Aug 15;75(5); Hogg RS, Eyawo O, Collins AB, et al. Lancet HIV. 2017 Jun;4(6)]. The increased prevalence of these diseases in PLWH has been attributed to HIV-related chronic inflammation and immunosuppression, treatment with specific antiretroviral agents, and coinfections, such as hepatitis C. In addition, PLWH may have traditional, non-HIV-related risk factors for these disease that require management beyond traditional HIV care. 

In people who do not have HIV infection, cardiovascular, liver, and kidney diseases are associated with clear risk factors, including hypertension, hyperlipidemia, and diabetes. Characterizing the prevalence of such chronic conditions among PLWH has important implications for care: If cardiovascular, liver, and kidney disease are primarily a result of HIV infection, then adjustments in HIV-specific management may abate or prolong end-organ disease. If traditional risk factors are also highly prevalent, then optimal management of these conditions will be an essential aspect of care for all PLWH.

Gallant and colleagues recently published results of a study that examined the prevalence of chronic, non-communicable, and end-organ diseases among people with and without HIV infection [Gallant J, Hsue PY, Shreay S, Meyer N. J Infect Dis. 2017 Dec 19;216(12)]. The researchers used claims data from private and public health insurers to determine the prevalence of specific non-communicable diseases among PLWH in 2013 compared with the prevalence among PLWH in 2003. In addition, they matched prevalence with a general population sample and compared prevalence between the two groups (PLWH and people without HIV infection) by year from 2003 to 2013. 

The research team used ICD-9-CM claims coding to describe co-morbidities and non-communicable diseases. Data for all individuals who were 18 years or older with at least 6 months of documented care were acquired from the private Truven Health Market Scan Commercial Claims Encounters database and from public Medicare and Medicaid claims. ICD-9-CM coding for HIV was used to identify PLWH: 36,298 patients with private insurance; 26,246 patients covered by Medicaid; and 1,854 patients covered by Medicare. PLWH were matched approximately 1:2 with non-HIV-infected controls.

Among PLWH, between 2003 and 2013, there was a substantial increase in the prevalence of multiple comorbidities, as illustrated in the table below.

These increases in prevalence of comorbidities between 2003 and 2013 indicate that multiple health conditions are common and are increasing among PLWH. The high prevalence of hypertension, hyperlipidemia, and diabetes substantially increases the risk of cardiovascular, kidney, and other diseases for PLWH.

When the researchers compared the matched populations (with and without HIV) by age and sex they found that the prevalence of hypertension, hyperlipidemia, and diabetes were roughly the same. Disease prevalence did vary slightly by type of insurance coverage. For example, the prevalence of diabetes was higher among Medicare patients without HIV (33.9%) than it was among those with HIV (29.5%). However, diabetes prevalence was the same for patients with private insurance, irrespective of HIV status. The prevalence of end-organ disease (cardiovascular, venous, liver, and kidney) was higher among PLWH, regardless of insurance type.

A yearly comparison of comorbidities between people with and without HIV infection revealed increases in disease prevalence in both groups (see the published article for interesting graphics). This suggests that the current high prevalence of some non-communicable diseases among PLWH likely represents an overall trend in morbidity and diagnosis or claims for those conditions. It does not appear that the increase in prevalence of non-HIV age-related comorbidities from 2003 to 2013 among PLWH is unique to HIV.

Optimal management of hyperlipidemia, hypertension, and diabetes begins with evidence-based behavioral (lifestyle) interventions and medical management. Clinicians caring for people who are living and aging with HIV infection in 2018 will have to be able to manage hypertension, hyperlipidemia, and diabetes (or refer patients for care) as well as they manage ART to improve and maintain the health of their patients.

PrEP: Progress and Challenges in the Elimination of HIV Transmission (11/2/17)

Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine

The elimination of HIV transmission may be achievable if increases can be realized in both the proportion of people with HIV infection who maintain an undetectable viral load and the proportion of people at highest risk of acquiring HIV who are using pre-exposure prophylaxis (PrEP). Several studies (PROUD, IPERGAY, IPREX) have demonstrated the efficacy of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC; Truvada) PrEP to prevent HIV infection. However, 5 years after FDA approval of PrEP in the United States, many of those at highest risk of HIV infection still are not aware of or are not using PrEP. As of the first quarter of 2017, an estimated 136,000 people were being prescribed PrEP in the U.S. However, groups in critical need-younger men who have sex with men (MSM), particularly African American MSM-are not receiving PrEP. 

Two recently published studies, discussed below, highlight the promise, progress, and challenges associated with PrEP and any effort to scale-up to a level that could result in the elimination of HIV transmission. The first provides evidence that changes in risk of acquiring sexually transmitted infections (STIs) do occur among men on PrEP, but any increase in STIs appears to be minimal. The second is a small study of offering PrEP to participants in an observational cohort of MSM at higher risk of HIV. That study highlights barriers to PrEP uptake that extend beyond a lack of knowledge and willingness among clinicians and beyond drug cost and lack of insurance coverage among potential users of PrEP. 

PrEP Use and STIs 

Molina and colleagues examined behavioral change in an analysis of an open-label PrEP continuation phase of the randomized double blind IPERGAY PrEP trial [Molina JM, Charreau I, Spire B, et al. Lancet HIV. 2017 Sep;4(9)]. The researchers compared reported behavior and STI incidence during the randomized study period, in which participants received either placebo or PrEP, to STI incidence during the open-label PrEP continuation phase, when all participants received PrEP and knew they were getting it. In this study, the number of reported sex partners and sex acts remained stable, with a modest increase in condomless anal sex (77% to 86%). A numerical increase in bacterial STIs (from 59 to 69 per 100 person-years) was also identified; though the incidence remained high, the  increase was not statistically significant. 

Results of this study suggest that (1) there is a population at high risk of acquiring HIV and STIs that can benefit from PrEP and (2) PrEP markedly reduces HIV incidence without leading to a substantial increase in STIs or other potential harm. Educating people about STI risks and encouraging condom use remain important components of sexual health care in general. However, the incidence of STIs in this study demonstrates the valuable role of PrEP in preventing HIV infection among a population at persistently high risk. 

Complex Behavioral Barriers to PrEP 

Despite positive results on PrEP benefits, many of those at highest risk of HIV infection in some populations are not using PrEP. Awareness, marketing, and access have been identified as barriers; in a just published observational study of HIV risk and incidence, the researchers describe interest in and uptake of PrEP among a cohort of young black MSM (YBMSM) participating in the EleMENt longitudinal cohort study [Rolle CP, Rosenberg ES, Siegler AJ, et al. J Acquir Immune Defic Syndr. 2017 Nov 1;76 (3)]. The YBMSM study participants were recruited in Atlanta, GA., between July and December 2016 through social media, venue sampling, and advertisements in public transport. The box below summarizes characteristics of participants.

At enrollment, participants were screened for HIV, other STIs, and substance use. The researchers subsequently provided education about PrEP and offered it to participants who tested negative for HIV infection. PrEP costs were not directly covered by the study, but the study team sought to provide PrEP at no cost through use of private insurance and medication assistance programs; no incentives were provided for PrEP-specific visits. 

Study participants (N = 192) and characteristics:

  • Age: 16 to 29 years; median age 24 years
  • Sex: Male
  • Sexual identity: Most identified as gay; all reported ≥1 male sex partner in the previous 3 months.
  • Race: Black, non-Hispanic
  • HIV status: confirmed uninfected
  • Self-reported HIV risk factors:
    • Substance use: ~75%
    • Condomless anal sex within the prior 6 months: ~75%
    • STI diagnosis within the previous 12 months: 25%
  • Using PrEP at start of study: 4%
  • Heard of PrEP before study: 50%

At the time of study entry, 4% (8) of participants were already using PrEP, which left 184 participants eligible for PrEP initiation. Of those, approximately 50% reported that they had heard of PrEP previously. When PrEP was offered, 10% of participants were not interested, 27% wanted to discuss PrEP further at the next study visit, and 63% (116) were interested and scheduled for an initiation visit. However, only 37 attended a PrEP initiation visit despite repeated attempts by the study staff to schedule a visit. By the end of the observation period, only 34% (63) of participants had initiated PrEP.

The only statistically significant difference between those who started PrEP and those who did not was a higher proportion reporting an STI in the past 12 months: 33% of those starting PrEP and 20% of those not starting PrEP. There was no statistical difference in age, but the proportion of participants over the age of 24 years was greater among those starting PrEP: 67% compared to 54%. The proportion who reported having previously heard of PrEP was also higher among those who started PrEP: 60% versus 49%. Income, sexual identity, relationship status, substance use, and having had an HIV test in the past 12 months were not correlated with choosing to use PrEP. The team also explored reasons for interest or disinterest in PrEP and found that 24% of PrEP users vs. 37% of non-users agreed with the following statement: “I always use condoms,” and 3% of PrEP users vs. 22% of non-users agreed with the following statement: “I would be unhappy about taking a pill every day.”

Important behavioral factors beyond the scope of this study appear to mediate use of PrEP. This study has important limitations: It included a very small sample size and was geographically limited. Clearly, additional behavioral research is needed to understand how to communicate effectively with diverse groups at higher risk of HIV. 

Challenges in PrEP Scale-Up

These two studies highlight important considerations regarding HIV prevention through increased use of PrEP. The first consideration is that individuals who are most likely to benefit from PrEP have a high incidence of STIs. The STI incidence in Molina’s study confirms that this is a group also at high risk of HIV infection. It also validates the importance of getting PrEP to YBMSM and others who, for a variety of reasons, including number of sex partners and lack of condom use, are at highest risk of acquiring HIV and other STIs. We need to reach this population with PrEP. The second consideration is the on-the-ground challenges to increasing PrEP uptake among a higher risk group in a setting without barriers to access. Public health professionals, community activists, and primary care doctors all have important roles in developing communication strategies and providing effective health communication about PrEP, especially for those at higher risk of HIV infection. 

Does HIV Accelerate Age-Related Neurocognitive Decline? (9/17)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine

Advanced HIV disease and advanced age are both associated with impaired neurocognitive function. The emergent population of people living and now aging with HIV infection and being treated with potent antiretrovirals has little risk of developing classic HIV-related opportunistic illnesses. However, this population does appear to be at increased risk of conditions associated with aging, such as cardiovascular disease and frailty.

The authors of a recently published study [Goodkin K, Miller EN, Cox C, et al. Lancet HIV. 2017;4(9)] sought to evaluate whether HIV disease accelerates age-related neurocognitive decline. The authors analyzed a subset of data from the MACS (Multicenter AIDS Cohort Study) that included people with and without HIV infection, who had undergone repeated, extensive neurocognitive testing to assess functioning in five domains: information processing speed, episodic memory, executive function, motor function, and working memory. The researchers included medical and demographic data in their analysis to control for multiple potential confounders, such as education, income, alcohol use, other drug use, comorbid diseases, antiretroviral therapy era, HIV stage (using CDC staging), and duration of infection since HIV seroconversion.

Advanced age (>50 years) and advanced HIV stage were each associated with lower neurocognitive scores. Increasing age was associated with lower scores across all domains. Participants with CDC Stage A or B HIV (asymptomatic or early symptomatic) had neurocognitive scores similar to those without HIV. However, those with Stage C HIV (AIDS) had lower scores for motor function and working memory. Furthermore, there was an interaction between aging and advanced HIV leading to a multiplicatively greater decline in motor function and episodic memory.

When the model included time since seroconversion, people living with Stage C HIV (AIDS) also had significantly lower scores on motor function and episodic memory and a greater decline in both with aging, when compared with those with less advanced HIV or those uninfected with HIV. The researchers described an anatomical correlate that may explain these motor function and episodic memory results: The basal ganglia and hippocampus are both affected by HIV, often with early involvement. Motor function depends on the basal ganglia, and the hippocampus is critical for episodic memory.

This study highlights the value of neurocognitive testing to evaluate potential cognitive decline in people living with HIV. Results can help to quantify the level of impairment and help guide diagnoses. The study results suggest that, in a patient with a history of advanced HIV infection, a finding of greater decline in motor function and episodic memory than in other domains is consistent with primary HIV-related brain disease. If other patterns of neurocognitive decline–in executive function, for example–are identified, then a non-HIV-related cause may be more likely and further evaluation may be warranted. 

Questions still to be answered include: (1) What is the long-term effect of HIV infection on someone started on antiretroviral therapy soon after seroconversion who maintained an undetectable viral load long-term? (2) What is the effect of HIV infection among individuals >70 years of age? (3) What is the potential effect on neurocognitive performance over time of HIV medications that are neurotoxic or that have greater central nervous system penetration? I look forward to future publications from this and other groups to further explain the long-term neurocognitive implications of HIV infection and successful HIV treatment.

Risk of Frailty Among People with HIV (7/17)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine

Effective antiretroviral therapy (ART) is enabling people with HIV infection to live longer. As a result, the HIV-related morbidity experienced by this aging population is shifting from illness caused by opportunistic infections to illness caused by chronic, non-communicable cardiovascular, kidney, and liver diseases. This population is also subject to frailty, an age-related cognitive and functional decline that can decrease a person’s physiological reserve and increase vulnerability to external stressors.

Characteristics associated with frailty: In the HIV-related peer-reviewed literature, frailty is often defined as the presence of 3 or more of the following 5 characteristics: unintentional weight loss, exhaustion, weakness, low physical activity, and slowed walking speed. Frailty increases the risk of falls, hospitalizations, and death; thus, it is the subject of increasing research and clinical attention.

A recently published study by Erlandson and colleagues [J Infect Dis, 2017 Mar 15;215(6)] sought to identify modifiable risk factors for frailty in patients taking ART. The researchers analyzed the frailty assessments of 1,016 participants from the ACTG A5322 observational cohort study, which had recruited participants from prior ACTG studies. All participants were aged ≥40 years, and 85% were aged <60 years; 19% were females; and 48% were White non-Hispanic, 30% were Black non-Hispanic, and 20% were Hispanic. Upon study entry, participants’ frailty was assessed as follows:

  • Walking speed and grip strength: Observation
  • Weight loss: Self-report
  • Low physical activity and exhaustion: Quality of life scales
  • Demographics, economic status, and medical characteristics: Historical study data

Of all study participants, 6% met criteria for frailty, and 38% were pre-frail (had 1 or 2 of the 5 frailty components). Risk factors associated with frailty included the following:

  • Female sex
  • Non-white
  • Receiving Medicaid or Medicare benefits
  • Older age
  • Smoking
  • Less education
  • Lower physical activity
  • HCV antibody positivity
  • Neurocognitive impairment
  • Obesity

ART associated with frailty? Efavirenz use appeared to increase risk of frailty in the overall analysis, but not in an analysis limited to participants whose initial regimen had been randomized to efavirenz or atazanavir in a prior study (ACTG 5202). Integrase strand transfer inhibitors (INSTIs) had a stronger association with a non-frail state. The authors argue, and I agree, that the findings regarding specific ART agents and frailty should be interpreted with caution because this is not a randomized clinical trial. It is an observational study, and multiple factors may have influenced ART selection. In addition, INSTIs are a newer class of antiretroviral drugs and may reflect changes in care or participant characteristics over time. 

Risks: What was most striking in this study is that many of the factors associated with increased risk of frailty represented structural inequality, such as being a recipient of public health benefits or having less than a high school education. Moreover, factors that are often associated with structural inequality were also associated with increased frailty: female sex, race other than White, poverty, smoking, and obesity. 

These results suggests that preventing frailty may require far more than choosing ART regimens carefully. That said, it’s clear that more studies are needed to better understand how to address frailty and pre-frailty once those conditions are identified. 

High-Grade Anal Intraepithelial Neoplasia Recurrence (6/17)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine

HIV-infected men who have sex with men (MSM) have a higher risk of anal cancer than men in the general population (65 to 130 per 100,000 person-years versus 5 to 15 per 100,000 person-years). High-grade anal intraepithelial neoplasia (AIN) is considered the precursor to anal cancer, which has high morbidity and mortality rates. High-grade AIN can be suspected on the basis of an abnormal anal cytology result (generally, high-grade squamous intraepithelial lesion or SIL). Although limited data are available to support a specific screening and management approach, abnormal anal cytology is generally followed-up with anal biopsy via high-resolution anoscopy (HRA). Histologically proven high-grade AIN lesions can be ablated using electrocautery, cryotherapy, or chemical means. However, recurrence after treatment persists, as shown in a recently published study that examined factors associated with high-grade AIN recurrence after successful ablation.

The study authors [Burgos J, et al. AIDS 2017 Jun 1;32(9)] used data collected from an observational cohort of MSM with HIV infection whose care was managed in an anal dysplasia clinic at a hospital in Spain. All patients were diagnosed with high-grade AIN and had biopsy-proven response to electrocautery 6 to 8 weeks after their last treatment session. Follow-up with HRA continued every 3 to 6 months. Recurrent high-grade AIN was defined by biopsy either at the previously treated site or an untreated site.

The study included 141 participants with high-grade AIN who accepted treatment. Of these, 100 (71%) had successful treatment. The median age of successfully treated patients 43 years; the mean CD4 count was 629 cells/mm3, and 70% had an undetectable viral load at the time of treatment. The participants were followed for a median of 13.6 months. During the follow-up period, 39 (39%) developed recurrent high-grade AIN; no patients progressed to invasive anal cancer.

Of those with recurrent high-grade AIN, 37/39 (95%) had a larger initial lesion (lesion affecting two or more octants of the anal canal circumference) than did those without recurrence (45/61 [74%]). Those with recurrence also had a lower nadir CD4 count (232 vs. 326 cells/mm3) and were more likely to have HCV antibodies present (16% vs. 2%). 

Factors not associated with recurrence of high-grade AIN included age, undetectable viral load, a current and stable sex partner, and routine use of condoms.

After 1 year of treatment, 57% of participants had high-grade neoplasia (41 patients did not respond to initial treatment and 39 patients experienced recurrence). This appears to be a remarkable failure rate for any therapy. This result raises several questions regarding the most effective management of anal neoplasia: What is achieved through electrocautery ablation? Is the risk of anal cancer being reduced with this treatment? How frequently should follow-up occur? What risk factors predict progression to anal cancer?

The take-home message for me is that high-grade anal neoplasia is common and the success with current treatment approaches is limited. There remains a need for improved data and guidance on optimal approaches to managing and preventing anal cancer among MSM.

Vitamin D Deficiency Associated with Statin-Induced Muscle Toxicity in Patients Living with HIV (3/17)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine

A recently published study supports the association between statin-related myalgia and vitamin D deficiency among people treated with antiretroviral (ARV) agents, with an impressive effect size of 2.3 [Calza L, et al. AIDS 2017 Mar 13;31(5)].

Several antiretroviral (ARV) agents are associated with hypercholesterolemia. In addition, some ARVs, and a pro-inflammatory state caused by HIV itself, can increase the risk of cardiovascular disease (CVD). For these reasons, both hypercholesterolemia and CVD appear to be increased among people living with HIV. Statins play an important role in managing hypercholesterolemia and in reducing the risk of CVD, thereby reducing mortality, among patients living with HIV. The American College of Cardiology and the American Heart Association recommend statins for all individuals at high risk of cardiovascular disease [Stone NJ, et al. J Am Coll Cardiol. 2014 Jul 63(25 Pt B)]. Whether a role for statins exists among people living with HIV who are at low to moderate risk of cardiovascular disease is being evaluated in the REPRIEVE study.

Adherence to statin treatment can be compromised by muscle toxicity. In the general population, between 10% and 25% of individuals taking statins report having myalgia, and many discontinue the therapy as a result. Further, vitamin D deficiency has been associated with statin-induced myalgia in the general population. Given the frequency of vitamin D deficiency among people living with HIV (70%-84%), Calza and colleagues [AIDS 2017 Mar 13;31(5)] performed a retrospective analysis in Italy on a cohort of 545 patients taking ART and either atorvastatin or rosuvastatin. The primary study goal was to evaluate the association between vitamin D level and muscle toxicity using the following markers: myalgia, elevated creatinine kinase level in the absence of myalgia, or myalgia and elevated creatinine kinase level.

The majority of patients were male (80%) and white (91%); 95% had an undetectable viral load. Muscle toxicity was identified among 100 patients (18%), evidenced by myalgia in 42, elevated creatinine kinase without myalgia in 33, and elevated creatinine kinase with myalgia in 25. There was no statistically significant difference in muscle toxicity between patients taking atorvastatin or rosuvastatin. The median time to muscle toxicity was 412 days, with 10% of patients having toxicity within 34 days of starting a statin. Vitamin D deficiency was associated with muscle toxicity. Among patients with muscle toxicity, the vitamin D level was 19 to 22 ng/mL (depending on presence of myalgia or elevated creatinine kinase level), compared with a level of 32 ng/mL among patients without muscle toxicity. Among the 40 patients with a vitamin D level available at the time of myalgia or elevated creatinine kinase diagnosis, the level was similar to that at baseline. In an adjusted analysis, factors associated with muscle toxicity were age older than 60 years, history of myalgia, vitamin D levels lower than 30 ng/mL (odds ratio, 2.3), and longer duration on statin therapy. Notably, therapy with a boosted-protease inhibitor was not associated with an increased myalgia risk.

Two observational studies in the general population suggest that supplementing vitamin D when the level is low may reduce the occurrence of statin-related myalgia [Glueck CJ, et al. Curr Med Res Opin. 2011 Sep;27(9); Khayznikov M, et al. N Am J Med Sci. 2015 Mar;7(3)]. Randomized trials of vitamin D supplementation to reduce statin myalgia have not been completed in the general population or among people living with HIV. However, given the frequency of vitamin D deficiency in patients living with HIV and the potential benefits of a normal vitamin D level on bone health and immune activation [Overton ET, et al. Ann Intern Med. 2015 Jun16;162(12); Fabre-Mersseman V, et al. AIDS. 2014 Nov 28;28(18)], treating vitamin D deficiency with oral vitamin D3 supplementation is reasonable. Achieving a normal vitamin D level may also reduce statin-induced myalgia, increasing the chance of success with statin therapy and ultimately reducing cardiovascular disease.  

Subscribe to receive Topics, Trends & Updates by email.

Quality of Life Improvement with Early ART Initiation (2/17)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine 

Results of a just-published study suggest that, in addition to reducing all-cause mortality and improving health overall for patients with HIV infection, early initiation of ART also improves quality of life (QOL). Using data collected at baseline and during follow-up visits for the START trial, Lifson and colleagues assessed whether timing of ART initiation affected patients’ self-assessed QOL (Lifson, AR et al. AIDS. 2017 Apr 24;31(7)).

The START trial, which was conducted in 35 countries, randomized 4,685 participants with CD4 counts >500 cells/mm3 to one of 2 arms: immediate ART initiation or ART initiation at CD4 count <350 cells/mm3. Roughly 50% of participants lived in high-income countries and 50% in low- and middle-income countries. Approximately 75% received an initial ART regimen containing efavirenz, an agent well known to cause CNS and mood side effects.

At each study visit, patients were asked to assess their QOL using 2 methods–a visual analog scale to record their perceived current state of health (scored 0-100) and the SF-12, a widely used survey that includes physical and mental health components. 

QOL data were collected for 4,561 START trial participants, distributed evenly between the immediate and deferred ART study arms. At baseline, physical and mental health scores were similar between the two arms. By 4 months they diverged, with scores improving in the immediate ART arm and remaining relatively unchanged in the delayed ART arm. Scores of deferred ART patients were censored from analysis upon ART initiation.

The difference in QOL scores persisted: throughout 5 years of follow-up; when individuals with severe events were excluded; and through multiple subgroup analyses, including age, gender, race, geographic region, baseline CD4 count, efavirenz ART, and baseline visual analog scale.

This analysis provides further support for universal access to ART upon diagnosis of HIV infection: ART reduces severe health events, reduces HIV transmission, and improves quality of life for otherwise healthy people living with HIV.  

Subscribe to receive Topics, Trends & Updates by email.

A High Rate of Dolutegravir Side Effects in "Real-World" Settings (1/17)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine 

In my practice, 5% to 15% of the patients I start on dolutegravir (DTG) experience intolerable headaches or insomnia that necessitate a switch to another agent. This level of intolerance is higher than reported from clinical trials. I always wonder whether the patients of other clinicians have had the same “real-world” experience with DTG side effects and now several recent studies shed light on this issue. 

In one study, researchers from the Netherlands [de Boer MG, et al. AIDS. 2016 Nov 28;30(18)] reported on the tolerability of DTG among 556 patients initiated on DTG between August 2014 and March 2016. DTG was stopped in 76 patients (13.7%) due to adverse drug reactions after a median of 73 days (range 5-327). The combination of DTG with abacavir (ABC) led to a higher overall discontinuation rate (16.3%). The majority of side effects were neuropsychological or psychiatric (insomnia, headaches, mood alterations, and malaise) and gastrointestinal. Discontinuation for neuropsychiatric side effects was 2.3 times more likely among patients taking DTG plus ABC.

Other researchers have also reported neuropsychiatric side effects with DTG. Researchers in Germany [Hoffmann, C et al. HIV Med. 2017 Jan;18(1)] evaluated a cohort of 1,704 patients who initiated an ART regimen containing an integrase strand transfer inhibitor (ISTI) between January 2007 and April 2016. The rates of adverse events leading to discontinuation within 12 months were 7.6% for elvitegravir (EVG), 7.6% for DTG, and 3.3% for raltegravir (RAL). Renal side effects were the leading cause of EVG discontinuation (3.5%); neuropsychiatric side effects were most commonly reported with DTG (5.0%). The most common neuropsychiatric symptoms among the 49 patients who discontinued DTG were insomnia and other sleep disturbances, dizziness, headache, poor concentration or slowed thinking, depression, and painful paresthesia.

An older (2015) case series from France that includes four patients [Kheloufi, F et al. AIDS. 2015 Aug 24;29(13)] described the following symptoms post-DTG-initiation: fatigue and “drunk feeling” in patient 1, headaches and depression in patient 2, worsening psychiatric symptoms in patient 3, and intense headaches (which spontaneously resolved) followed by suicidal ideation in patient 4. 

DTG is a highly potent agent with a high barrier to resistance and unparalleled outcomes in randomized trials [Cahn, P et al. Lancet. 2013 Aug 24;382(9893); Clotet, B et al. Lancet. 2014 June 28;383(9936); Walmsley, SL et al. N Engl J Med. 2013 Nov 7;369(19)], and it appears to be very well tolerated in most patients who do not experience side effects. For these reasons, it has an important role in current antiretroviral therapy (ART). However, assessing for side effects and correctly identifying DTG as a potential cause of new and unexpected symptoms in the days to weeks after initiating this drug is essential to optimal care. My experience with the side effects with DTG has taken a little of the shine off this potent agent and has led me to consider the potential for DTG-associated side effects when selecting a regimen for an ART-naïve patient or planning a switch for failure or convenience.    

Subscribe to receive Topics, Trends & Updates by email.

Is Memory Really the Problem in ART Adherence? (10/16)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University

An undetectable HIV viral load is the sine qua non of effective antiretroviral therapy (ART). Once the correct ART regimen is prescribed, achievement of an undetectable viral load then depends on sustained adherence. The authors of a recent study in AIDS Care (Kalichman SC, et al. AIDS Care. 2017 Apr;29(4).) sought to better understand and differentiate between factors associated with moderate and severe non-adherence. Moderate non-adherence was defined as 75% to 95% of medication doses taken as prescribed; severe non-adherence was defined as <75% of doses taken as prescribed.

The authors used computerized interviews to collect patient self-reported data on symptoms, side effects, use of common reminder strategies, depression, life stress, and alcohol consumption. The authors also used urine testing to assess for recent illicit drug use. Over a 1-month period, participants were contacted three times for telephone-based pill counts. Participants who had missed doses were then asked about cognitive, organizational, mental health, substance use, and structural barriers to adherence. 

The team followed 214 severely non-adherent and 342 moderately non-adherent participants for 1 month. A large and equal proportion of patients in each group used memory aids to support adherence, including pill boxes, alarms, routine timing of pills, journals, reminders from family members, or posted reminder signs. Although a larger proportion of the severely non-adherent participants reported having forgotten or having been too busy to take medications, the number was not statistically significant. Of the severely non-adherent, 54% reported forgetting compared with 41% of the moderately non-adherent. A larger and statistically significant difference in adherence was related to side effects, running out of pills, and consumption of alcohol (see table below). Depression and stress were also higher among severely non-adherent participants.

Factors Affecting ART Adherence Participants Reporting this Effect,          by Level of Non-Adherence
Severe Moderate
Medication side-effects 12% 4%
Running out of pills 21% 9%
Consumption of alcohol 21% 13%

The results of this study suggest that even when adherence reminder strategies are used, they are not effective in helping patients overcome factors related to both severe and moderate non-adherence, including, in this group, alcohol use, access to medications, and mental health challenges. 

This study did have some limitations. The researchers followed participants for just 1 month, and the results were not strong: 68% of the severely non-adherent had undetectable viral loads, and less than 50% of non-adherence among participants was associated with the factors named above.

Nonetheless, the results highlight the roles that mental health, substance use, and structural barriers may play in reducing adherence to ART. The findings also suggest that other, yet-to-be identified factors are at play as well. Perhaps most importantly, the standard focus on memory, reminders, and memory aids may not be helpful in significantly improving adherence among those with demonstrated non-adherence, and we need to dig deeper to help our patients take the medications that will suppress their viral loads.

Subscribe to receive Topics, Trends & Updates by email.

Successful Same-Day ART Initiation with a Complex Patient Population (8/16)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University

A move to test and initiate treatment on the same day will require changes in traditional approaches to HIV management. Those changes may include restructuring clinic services and identifying individuals who are the best candidates for immediate antiretroviral therapy (ART) initiation. A recent article (Pilcher et al. J Acquir Immune Defic Syndr. 2017 Jan 1;74(1)) describing immediate ART initiation by the San Francisco General Hospital outpatient HIV clinic provides insight into both issues.

Beginning in July 2013, the clinic began to offer same-day ART initiation with a protocol called RAPID. During the entire reported period (6/2013 to 12/2014), only patients lacking private insurance were eligible. In the first 6 months, eligibility for RAPID care was also limited to patients with acute or recent HIV infection, but criteria were liberalized after January 2014. Patients were referred from outpatient clinics and HIV testing centers in San Francisco, and taxi vouchers were available for patients to be transported from across the city. 

The RAPID protocol provided same day HIV education, blood draws for laboratory testing, accelerated insurance approval efforts, and a directly observed first ART dose. Patients for whom insurance approval was not obtained were given a 5-day starter-pack. This process took 3 to 4 hours. Within the 7 days after the initial visit, a nurse followed up by phone.

During the 18 month study period, 39 patients who would be considered “complicated” in most treatment settings were initiated on the RAPID protocol (2 patients per month). Patients’ CD4 counts ranged from 3 to 1391 cells/mm3, 27% were considered homeless, 42% had a “major” mental health disorder, and 42% reported use of any illicit substance. Despite these challenges, 37 patients (95%) initiated ART within 24 hours of their clinic visit. Approximately 90% had a viral load <200 copies/mL within 6 months after clinic referral. Only 4 (10%) were lost from care (no visit in a 6 month period); 8 (20%) transferred care to another clinic.

Although limited by its very small sample size and low volume of patients during the observation period (2 patients per month), this report is valuable for its description of a same-day ART initiation program that succeeded with complex patients. With the right clinical resources, these results suggest that most people living with HIV can initiate ART rapidly with success. This report also underscores that ART should not be delayed automatically because of mental illness, substance abuse, and/or unstable housing. 

Subscribe to receive Topics, Trends & Updates by email.

Blood Pressure Control and Medication Adherence among People Living with HIV (7/16)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University

Hypertension is a common comorbidity among people living with HIV (PLH), affecting 20% to 43%. This proportion is likely to grow with the aging of the PLH population (see Okeke NL, et al. Clin Infect Dis 2016 Jul 15;63(2), for time trends in HTN diagnosis among PLH). Recent studies suggest the need to educate patients about the risks of uncontrolled hypertension (HTN).

The pivotal 2015 SPRINT study [SPRINT Research Group, et al. NEJM 2015 Nov 26;373(22)] quantified a reduction in mortality and cardiovascular outcomes with tight versus routine HTN control among individuals who were not HIV-infected. This large, randomized, controlled trial involved 9,361 individuals 50 years of age and older with a systolic blood pressure (SBP) between 130 and 180 mmHg (median 140 mmHg) and cardiovascular risk factors other than diabetes. Participants were randomized to one of two arms, with results reported after a median 3.3 years of follow-up. Results are summarized in the table below.

  Treatment Arm
Participants Standard Intensive
Number 4,683 4,678
Target SBP mmHg <140 <120
Median no. HTN meds 1.8 2.8
Serious adverse events 2.5% 4.7%
No. reaching primary clinical outcome
(hazard ratio = 0.75, p < 0.001)
319 243

The primary clinical outcome was defined as one of the following: myocardial infarction, acute coronary syndrome, stroke, heart failure, or cardiovascular death. All-cause mortality was also substantially lower (hazard ratio = 0.73, p = 0.003) in the intensive treatment arm. Approximately 38% of participants in each arm experienced side effects, although serious adverse events, such as hypotension, syncope, electrolyte abnormalities, and acute kidney injury, were higher in the intensive treatment arm. In all, the SPRINT study demonstrated that a goal of SBP<120 mmHg reduced mortality and cardiovascular outcomes among individuals over the age of 50.

The PLH population already on antiretroviral therapy (ART) has experience with multiple medications and with regimens that require adherence as strict as those for HTN. 

Weiss and colleagues [J Acquir Immune Defic Syndr. 2016 Dec 1;73(4)] recently studied the effects of adding both medications and exhortations for strict adherence to the treatment regimens of HIV-infected participants. The researchers recruited 117 participants with HIV and HTN and 37 participants with HIV and chronic kidney disease (CKD) and followed them with health belief surveys and electronic monitoring of adherence to HIV, HTN, and CKD medications. At the 10 week follow-up, 88% of participants had virologic control and 60% had HTN control (SBP<140 mmHg). However, there was no difference in adherence to ART and HTN medications.

ART adherence was associated with participants’ reports of greater understanding of HIV, the perception of greater severity of HIV, and the view that ART medications are more necessary than medications for other conditions. This study suggests that HTN control is worse than virologic control among PLH, even though adherence to the two types of medication may be similar.

Taken together, the results of these two studies suggest that clinicians caring for PLH may need to intensify efforts to educate patients about HTN and its consequences and the potential benefit of a blood pressure even lower than the standard <140 mmHg. 

Subscribe to receive Topics, Trends & Updates by email.

Cardiovascular Risk Scores and CVD Risk Reduction among People Living with HIV (6/16)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University

Primary methods of preventing cardiovascular disease (CVD) with smoking cessation, control of hypertension, and use of aspirin and HMG-CoA reductase inhibitors can substantially reduce the risk of myocardial infarction. Guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) recommend risk-based prescription of HMG-CoA reductase inhibitors. The ACC/AHA guidelines use a specific population-based risk calculator; however, other scores are also available, including the Framingham Risk Score and the D:A:D cardiac risk score for people living with HIV (PLH). Among PLH, it remains unclear how well these scores predict risk of myocardial infarction caused by plaque rupture.

Monroe and colleagues [Monroe AK, et al. AIDS. 2016 Aug 24;30(13)] used data from the Multicenter AIDS Cohort Study (MACS), a multisite longitudinal cohort of HIV-infected and -uninfected men who have sex with men, to assess the performance of risk calculators for predicting coronary atherosclerosis, coronary calcium, or coronary stenosis of greater than 50%, as measured using cardiac computed tomography (CT). The authors reported a poor association between cardiac risk score and the presence of any plaque (area under the curve is 0.65 for PLH; an area under the curve of 0.5 indicates no correlation). Among PLH who were at low risk according to the ACC/AHA formula, 36% had a coronary artery calcium score greater than 0, 63% had any plaque (calcified and non-calcified), and 11% had greater than 50% stenosis. Performance was marginally better for those without HIV infection; however, 53% with any plaque and 5.4% with greater than 50% stenosis were in the low-risk category.

There are several potential interpretations of these findings:

  • The MACS population is different from everyone else, and risk calculators do not apply.
  • Compared with the general population, PLH have different needs and risk profiles for some aspects of primary care, such as CVD risk management, and calculators may not be the best approach to CVD risk management in PLH.

Limitations of this study include its use of a cohort that is not representative of the general PLH population and its use of coronary calcium score and atherosclerosis on CT as opposed to hard endpoints, such as CVD events.

Studies such as this raise questions regarding use of HMG-CoA reductase inhibitors among PLH. In other words, are we treating the right people? The ongoing REPRIEVE clinical trial is aimed at helping to answer this question.

Subscribe to receive Topics, Trends & Updates by email.

Predicting Kidney Disease Risk to Guide ART Selection (4/16)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University

Kidney disease is common among people living with HIV. Multiple factors, including HIV-associated nephropathy, antiretroviral therapy (ART), hepatitis B (HBV) or C (HCV) virus coinfection, diabetes, hypertension, and primary kidney disease can cause or contribute to kidney dysfunction. More common factors, though, are transient fluctuations in serum creatinine and estimated glomerular filtration rate (eGFR). Reducing the occurrence of comorbidities associated with kidney disease and limiting the diagnostic uncertainty of eGFR fluctuations may influence ART-prescribing decisions.

In a recently published article [AIDS 2016 Jun 1;30(9)], Flandre and colleagues report on the relationship between various initial ART regimens and the risk of chronic kidney disease (CKD). The researchers used a predictive score, developed and validated through the D:A:D cohort, that defined CKD as a persistent eGFR <60 mL per min per 1.73 m2.

The study cohort included 6,301 patients receiving care at 12 reference centers in France, all of whom initiated ART after January 1, 2004. All patients had at least one pre-ART and two on-ART creatinine measures, and eGFR was determined with the MDRD equation. Patients were stratified into low, medium, and high risk for CKD using the D:A:D score for CKD. This score accounts for a wide variety of factors, including type of HIV exposure (injection drug use [IDU] vs non-IDU), HCV coinfection, age, pre-ART eGFR, sex, nadir CD4 count, hypertension, cardiovascular disease, and diabetes. Incident CKD occurred in 211 (3.4%) of participants and was associated with older age, lower pre-ART eGFR, and lower nadir CD4 count. The probability of CKD by risk score was as follows: low risk, 0.65%; medium risk, 4.6%; and high risk, 15.9%.

CKD risk was highest for patients receiving a boosted protease inhibitor (PI) with tenofovir disoproxil fumarate (TDF). Risk was lower for patients receiving a non-nucleoside reverse transcriptase inhibitor (NNRTI) with or without TDF. Notably, among low-risk patients, the choice of an NNRTI vs a PI or TDF vs no TDF made no apparent difference in CKD risk.

This study is helpful in assessing the appropriateness of TDF or boosted-PI regimens for specific patients. For instance, avoidance of an initial ART regimen that includes TDF or a boosted-PI may be best for patients with a high D:A:D score for CKD. Patients with a low CKD risk score do not appear at increased risk for CKD from TDF or boosted PIs. These types of data may also be useful in securing insurer authorization to prescribe specific medications, such as tenofovir alafenamide (TAF)-containing combination tablets, and in discussing ART regimen side-effect profiles with patients.

Taking a risk-based approach when choosing an ART regimen does not require actual calculation, but taking into account a patient’s D:A:D score and risk factors for CKD is encouraged. Such an approach may reduce the number of patients requiring switches to less nephrotoxic regimens due to elevated eGFRs and may reduce the incidence of CKD among people living with HIV.

Subscribe to receive Topics, Trends & Updates by email.

Life Expectancy after an HIV Diagnosis (3/16)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University

One of the first questions a patient newly diagnosed with HIV may ask is, “How long will I live?” A new study from CDC researchers, which reports data on life expectancy from the time of diagnosis and average years of life lost (AYLL)*, may help in answering that question [Siddiqi, et al. J Acquir Immune Defic Syndr 2016 Jun 1;72(2)].

Using CDC HIV Surveillance Report data from all 50 US states and the District of Columbia, the researchers estimated life expectancy by year of HIV diagnosis for individuals reported to have been diagnosed during the four years from 2008 to 2011.  Life expectancy was further stratified by HIV exposure category, sex, and race/ethnicity.  The authors did not consider post-diagnosis factors such as engagement in care or virologic suppression.

Overall, between 2008 and 2011, the average life expectancy at the time of HIV diagnosis increased by 3.5 years, from 25.4 to 28.9 years. By transmission category, life expectancy at the time of diagnosis in 2011 was highest (32.3 years) among men having sex with men (MSM); it was lowest (20.2 years) among men injecting drugs. Analysis by race indicated that life expectancy was highest among Hispanic/Latinos, followed by blacks, whites, and other races (range: 26.1 to 30.8 years). Average years of life lost were not similarly stratified. With regard to sex, for all men diagnosed at age 25, the AYLL was 16.8 years; for women diagnosed at age 25, AYLL was 23.2 years.

This analysis demonstrates continued overall improvement in HIV survival, which may reflect increasing efforts to engage people living with HIV in care and to initiate antiretroviral therapy (ART). However, the analysis also highlights discrepancies in survival by population group, which most likely reflects better engagement in care among MSM than among injection drug users. And while the study reinforces the value of ART for achieving longevity, its findings suggest that nearly normal life expectancy with HIV infection depends not only on access to ART for all patients but also on support to overcome systemic social, economic, and substance use challenges and maintain engagement in care and adherence to ART.

*AYLL is calculated by subtracting life expectancy with HIV from life expectancy for the general population. 

Detection of Invasive Anal Cancer in HIV-Infected Patients (1/16)

By Christopher J. Hoffmann, MD, MPH, Johns Hopkins University School of Medicine

Although invasive anal cancer is relatively rare, the disease can be devastating. The incidence of this cancer is increased among people living with HIV, especially among those who engage in receptive anal sex. For someone living with HIV in the United States or Canada, the cumulative incidence for anal cancer by the age of 65 has been estimated to be 1.3% compared with 0.03% for someone without HIV [Silverberg et al., Ann Int Med 2015 Oct 6;163(7)]. This cumulative incidence exceeds those for colorectal, liver, and pharyngeal cancer.

Clinical guidelines for prevention of anal cancer borrow heavily from the cervical cancer literature, with limited data to support specific screening and management practices. Routine screening generally includes anal cytology without HPV typing. A recent article by D’Souza and colleagues adds to the knowledge base of anal cancer. They studied the incidence and clearance of squamous intraepithelial lesions, as well as high-risk HPV infection, among HIV-infected and uninfected men who have sex with men (MSM) in the United States [J Acquir Immune Defic Syndr. 2016 Apr 15;71(5)]. The authors describe longitudinal follow-up for 1511 men with repeat anal cytology separated by 2 years; 723 were living with HIV; 788 did not have HIV. Most of those with HIV had undetectable viral loads (78%), and the median CD4 cell count was 583 cells/mm3. Abnormal cytology (of any kind) was identified among 40% of the men living with HIV and in 25% of those without HIV. Only 1.5% of men had high-grade squamous intraepithelial lesions. However, 2.4% had atypical squamous cells for which high-grade lesions could not be excluded. Among HIV-infected men who received repeat cytologic testing after initial ASCUS (atypical cells of undetermined significance) or low-grade squamous intraepithelial lesions, 56% regressed to normal cytology; 81% of those with high-grade cytologic findings regressed to a lower grade. High-risk HPV 16 was identified among 25% of men living with HIV and 16% of those without HIV. Among 220 men who received follow-up high-resolution anoscopy with biopsy after cytologic findings of high-grade lesions, 17% had histologically confirmed disease.

This study adds to the data on the high prevalence of anal HPV infection and cellular changes among MSM with HIV. It also highlights the limitation of cytology to identify individuals who should receive high-resolution anoscopy and biopsy, given the frequency of regression of lower-grade lesions to normal. Additional studies are underway that could shed more light on prevention of anal cancer and management of high- and low-grade lesions. Until results are available from those studies, the common practice of routine cytologic testing and referral for high-grade lesions, as well as for atypical squamous cells for which high-grade lesions cannot be excluded, remains a reasonable approach.

Subscribe to receive Topics, Trends & Updates by email.